Alkermes Shares Outstanding 2006-2021 | ALKS

Alkermes shares outstanding history from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Alkermes shares outstanding for the quarter ending June 30, 2021 were 0.164B, a 3.17% increase year-over-year.
  • Alkermes 2020 shares outstanding were 0.159B, a 1.12% increase from 2019.
  • Alkermes 2019 shares outstanding were 0.157B, a 1.25% increase from 2018.
  • Alkermes 2018 shares outstanding were 0.155B, a 1.11% increase from 2017.
Alkermes Annual Shares Outstanding
(Millions of Shares)
2020 159
2019 157
2018 155
2017 153
2016 151
2015 149
2014 145
2013 145
2013 137
2012 115
2011 96
2010 95
2009 96
2008 103
2007 103
2006 97
2005 90
Alkermes Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 164
2021-03-31 160
2020-12-31 159
2020-09-30 159
2020-06-30 159
2020-03-31 158
2019-12-31 157
2019-09-30 157
2019-06-30 157
2019-03-31 156
2018-12-31 155
2018-09-30 155
2018-06-30 155
2018-03-31 154
2017-12-31 153
2017-09-30 154
2017-06-30 153
2017-03-31 153
2016-12-31 151
2016-09-30 152
2016-06-30 151
2016-03-31 151
2015-12-31 149
2015-09-30 150
2015-06-30 149
2015-03-31 148
2014-12-31 145
2014-09-30 146
2014-06-30 154
2014-03-31 143
2013-12-31 146
2013-09-30 136
2013-06-30 143
2013-03-31 140
2012-12-31 137
2012-09-30 131
2012-06-30 135
2012-03-31 130
2011-12-31 130
2011-09-30 102
2011-06-30 97
2011-03-31
2010-12-31 96
2010-09-30 96
2010-06-30 95
2010-03-31
2009-12-31 95
2009-09-30 95
2009-06-30 95
2009-03-31
2008-12-31 96
2008-09-30 97
2008-06-30 97
2008-03-31
2007-12-31 104
2007-09-30 104
2007-06-30 104
2007-03-31
2006-12-31 105
2006-09-30 106
2006-06-30 94
2006-03-31
2005-12-31 97
2005-09-30 97
2005-06-30 90
2005-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.176B $1.039B
Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29